Expression of 3G11 epitope defines subpopulations of regulatory T cells with different suppressive potency.

Journal of the Neurological Sciences
Zhao ZhaoAbdolmohamad Rostami

Abstract

3G11, a sialylated carbohydrate epitope on the disialoganglioside molecule, is expressed predominantly on the surface of mouse CD4(+) T cells. Our previous studies suggested that lack of the 3G11 molecule could be a new cell surface marker for regulatory CD4(+) T cells. In the present study, we explore the relationship between 3G11(-) and CD25(+) T cells, a well-defined, naturally occurring regulatory T cell population. We found that a large proportion of CD25(+)CD4(+) T cells lack expression of 3G11 and that more 3G11(-)CD4(+) T cells express Foxp3 compared to the 3G11(+)CD4(+) population. Based on 3G11 and CD25 expression we sorted four CD4(+) T cell subpopulations and tested their phenotypes. Among four CD25/3G11-related CD4(+) T cell subpopulations, CD25(+)3G11(-) T cells expressed the highest levels of Foxp3 and IL-10 and most efficiently inhibited mitogenic and antigen-specific immune responses in vitro and clinical EAE in vivo, while CD25(-)3G11(+) T cells produced a higher level of proinflammatory cytokines and enhanced autoimmune responses. Thus, among CD4(+)CD25(+) T cells, CD25(+)3G11(-) T cells represent a more effective Treg subpopulation than CD25(+)3G11(+) T cells.

References

Nov 1, 1988·The Journal of Experimental Medicine·K Hayakawa, R R Hardy
Jan 1, 1995·Critical Reviews in Clinical Laboratory Sciences·R Martin, H F McFarland
May 16, 1994·Biochemical and Biophysical Research Communications·F DittrichP F Mühlradt
May 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·C C MaierM I Greene
Aug 3, 1999·The Journal of Experimental Medicine·C MillerR H Schwartz
Oct 18, 2000·The Journal of Clinical Investigation·J M BensonC C Whitacre
Jul 3, 2002·Nature Reviews. Immunology·Ethan M Shevach
May 7, 2003·The Journal of Experimental Medicine·Estelle BettelliVijay K Kuchroo
Aug 27, 2003·The Journal of Experimental Medicine·Sylvain FissonBenoît L Salomon
May 7, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Pedro L VieiraAnne O'Garra
Aug 3, 2004·Nature Medicine·Anne O'Garra, Paulo Vieira
Oct 20, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jayagopala ReddyVijay K Kuchroo
Jan 5, 2005·The Journal of Experimental Medicine·Shuang LiangMichele M Kosiewicz
Jul 12, 2005·The Journal of Clinical Investigation·Danila ValmoriMaha Ayyoub
Mar 7, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Guang-Xian ZhangAbdolmohamad Rostami
Aug 15, 2006·Immunological Reviews·Jens LohrAbul K Abbas
Aug 15, 2006·Immunological Reviews·Yasmine BelkaidIsabelle Suffia
Oct 20, 2006·European Journal of Immunology·Alison H BanhamElisabeth Suri-Payer
Feb 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gang Zhou, Hyam I Levitsky
Mar 24, 2007·Nature Reviews. Immunology·Daniel J Campbell, Steven F Ziegler
Jun 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ramesh K Selvaraj, Terrence L Geiger
May 20, 2008·Autoimmunity Reviews·Nadir AskenasyShai Yarkoni
May 31, 2008·Cell·Shimon SakaguchiMasahiro Ono

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.